Q4 Inc. Added to the 2021 List of Best Workplaces™ in Technology
17.11.2021 01:07:00 EET | Business Wire | Press release
Q4 Inc. (TSX:QFOR), (“Q4” or “the Company”) a leading capital markets communications platform, is proud to announce it has been added to the 2021 List of Best Workplaces™ in Technology. This distinction follows Q4’s recent designation as a Top 50 Best Workplaces in Canada, as well as a Top 50 Best Workplaces for Women and Top 50 Best Workplaces for Inclusion, for the third consecutive year.
Q4 is a capital markets communication platform that is designed to connect public companies, the buyside and sellside across their most critical workflows, namely investor relations, corporate access, research and deal management. Today, Q4 delivers innovative investor relations and corporate access solutions through their capital markets platform to more than 2,600 public companies and investment banks. Q4 also hosts over 13 million investors and sell-side analysts on its platform monthly to learn more about the companies in which they are invested.
Q4’s trusted, secure and highly scalable platform is designed to help all participants in the capital markets to connect the right company to the right investor, through the right bank at the best time. With this breadth of scale, Q4 has amassed vast amounts of data yielding proprietary insights into the behavior of capital markets participants. The company is in its early stages of mining those insights to benefit its customers.
Q4 has grown rapidly over the past few years, and recently completed its successful IPO on the Toronto Stock Exchange. The company has increased its employee base to over 500 globally, to serve its expanding customer base and continuously improve and broaden its product and services platform.
“Q4 is dedicated to fostering a workplace which is strongly connected, and is diverse, equitable and inclusive,” said Darrell Heaps, Chief Executive Officer. “We take great pride in our culture which is rooted in our shared values. These values form the basis of how we operate and enable us to develop and deliver innovative products and experiences to our customers. We have spent years focused on building Q4 to drive consistent growth and expansion, and are committed to executing our mission, for the benefit of our employees, our community, our customers and our investors.”
The Best Workplaces in Technology list, as well as the other named Best Workplace distinctions are based on direct feedback from employees of the hundreds of organizations that were surveyed by Great Places to Work®.
About Q4:
Q4 Inc. (TSX:QFOR), is a leading capital markets communications platform that is transforming the way publicly traded companies, investors, and investment banks make decisions to efficiently discover, communicate, and engage with each other. The Q4 end-to-end technology platform facilitates interactions across the capital markets through its IR website products, virtual events solutions, capital markets customer relationship management solution, and shareholder and market analytics tools. The firm is a trusted partner to over 2,600 public companies, including 50% of the S&P 500, as well as top tier investment banks. Q4 is based in Toronto, with offices in New York and London. To learn more about Q4, please visit www.q4inc.com.
About Great Place to Work®:
Great Place to Work is the global authority on high-trust, high-performance workplace cultures. Through proprietary assessment tools, advisory services, and certification programs, GPTW recognizes the world's Best Workplaces in a series of national lists including those published by The Globe & Mail (Canada) and Fortune magazine (USA). Great Place to Work provides the benchmarks, framework, and expertise needed to create, sustain, and recognize outstanding workplace cultures. Visit us at www.greatplacetowork.ca or find us on Twitter at @GPTW_Canada.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211116006392/en/
Contact information
Media:
Karen Greene, media@q4inc.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SWISSto12 and Mitsubishi Electric Corporation Announce Strategic Partnership14.9.2026 10:00:00 EEST | Press release
SWISSto12 today announced a memorandum of understanding (MoU) with Mitsubishi Electric Corporation (MELCO) (TOKYO: 6503) to pursue joint opportunities on advanced payloads, radio frequency (RF) products, and market development in Japan and the APAC region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260914982179/en/ Masahiko Arai, Executive Officer and Group President, Defense & Space Systems, Mitsubishi Electric, and Dr. Emile de Rijk, Chief Executive Officer, SWISSto12 Joint opportunities will leverage MELCO’s extensive satellite system expertise and integration capabilities together with SWISSto12’s proprietary 3D-printing designs and processes that form the foundation of its next-generation payloads—smaller, lighter, highly performant, yet built in materially shorter timeframes. The MoU underscores growing market adoption of SWISSto12’s HummingLink payload technology that leverages 3D-printing, with more than 2,000 pr
U.S. FDA Accepts New Drug Application Under Priority Review for Takeda’s Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment Expectations14.9.2026 10:00:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) under Priority Review for zasocitinib (TAK-279) for the treatment of adults with moderate-to-severe plaque psoriasis. Zasocitinib is an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, which demonstrated rapid, durable and consistent skin clearance in Phase 3 plaque psoriasis studies.1-3 Addressing unmet needs in psoriasis treatment “Despite progress in psoriasis care, there remains a need for highly effective oral therapies that also address the diverse and often challenging manifestations of psoriasis, including involvement of high-impact sites like the scalp,” said Andy Plump, M.D., Ph.D., president of R&D at Takeda. “Our Phase 3 data demonstrated rapid and durable skin clearance across various patient types and in high-impact and hard-to-treat areas. Based on the results across nearly 3,000 patients, zaso
Thales Builds Cryptographic Security for the Age of AI and Post-Quantum Computing14.9.2026 10:00:00 EEST | Press release
According to the 2026 Thales Data Threat Report, the threat of Harvest Now, Decrypt Later (HNDL) attacks was the top-cited risk, with 59% of organizations reporting that they are prototyping and evaluating post-quantum cryptography (PQC) algorithms to prepare for the quantum era. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804748922/en/ ©Thales To help organizations turn this readiness into deployment,Thales, a global leader in advanced technologies, today announced the launch of Luna 8, its next-generation hardware security module. Designed for the transition to post-quantum cryptography, Luna 8 enables organizations to securely store, protect, and manage cryptographic keys with market-leading performance, scalability, and speed. As organizations face growing pressure from emerging quantum threats, expanding AI workloads and evolving stringent regulatory requirements, Luna 8 provides the performance, security and cryp
Focused Support Launches Cavok STRIKE to Expand Link-16 Participation Across the Joint Force14.9.2026 08:00:00 EEST | Press release
Focused Support LLC today announced the launch of Cavok STRIKE, an integrated software capability that expands the Link-16 tactical battlespace picture by enabling additional operational platforms to participate in the Link-16 network. Modern battlefields have increasing numbers of unmanned systems, sensors, and supporting platforms operating throughout the joint battlespace. The rapid proliferation of Group 1, 2, and 3 UAS, including both expendable and recoverable systems, has created a growing need to integrate these assets into the broader tactical network. Many of these platforms provide operationally relevant information but have historically remained outside the Link-16 network due to limitations in size, weight, power, platform integration complexity, or acquisition cost. Cavok STRIKE addresses this gap by enabling platforms to participate in the Link-16 network as non-command-and-control participants. This allows those platforms to interoperate with traditional Link-16 platfor
Fujirebio Expands Access to Blood-based Neurology Testing in Brazil with ANVISA Market Authorization for Lumipulse® G NfL Blood and Lumipulse G pTau 217 Plasma14.9.2026 08:00:00 EEST | Press release
H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that the Brazilian Health Regulatory Agency (ANVISA) has granted market authorization for the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays for use on the fully automated LUMIPULSE® G immunoassay platform in Brazil. “ANVISA authorization of the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays marks another important step in our mission to expand access to reliable, clinically meaningful blood-based biomarkers for clinicians and patients worldwide,” said Christiaan De Wilde, CEO of Fujirebio Europe N.V. “By making both neurological biomarker assays available to laboratories on a single, fully automated platform, we are helping support more informed clinical decision-making across a broad range of neurological conditions and throughout the diagnostic pathway.” The Brazilian ANVISA authorizations are based on the already CE marked in vitro diagnostics (IVD) approvals of these two
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom